Anavex Life Sciences Corp (AVXL)

[nidan7500]

TOLD YA...Precision Med follow up...WOW....getting closer...very , very nice...getting closer to the next level discussion and accelerated problem solving models...

Recent genetic research has identified connections between schizophrenia and Alzheimer disease, suggesting shared mechanisms between the 2 disorders. Notably, a successful trial of Karuna Therapeutics’ dual M1/M4 muscarinic receptor agonist, KarXT (xanomeline-trospium), in individuals with schizophrenia has shown efficacy in treating both positive and negative symptoms,1 leading the FDA to grant the treatment a Prescription Drug User Fee Act (PDUFA) date of September 26, 2024.2 Muscarinic agonists have been explored in the context of Alzheimer disease and schizophrenia in previous studies.1

“Schizophrenia is a serious mental illness affecting 24 million people worldwide,” said Christopher U. Missling, PhD, president and chief executive officer of Anavex Life Sciences Corp, developer of Anavex 3-71, in a press release. “While current antipsychotic therapies can be effective in managing positive symptoms, like hallucinations and delusions, they may not fully address persistent negative symptoms or cognitive difficulties. Often, available treatments are limited by side effects, eg, movement disorders, sedation, weight gain, and other metabolic side effects.”

Research shows that approximately 30% of individuals with schizophrenia to not respond to therapies, and additional 50% either experience intolerable adverse effects or only experience partial improvement in their symptoms.1

To address all of this, Anavex aims to leverage its Precision Medicine Platform by studying Anavex 3-71 alongside blarcamesine (Anavex 2-73), an orally available drug candidate that reestablishes cellular homeostasis by targeting muscarinic and SIGMAR1 receptors. The company is studying this combination of drug candidates in order to offer potential treatment options for Alzheimer disease and schizophrenia.1

Anavex 3-71, with its selective SIGMAR1 receptor activity, presents a new pharmacological approach to address disruptions to neuronal homeostasis observed in individuals with schizophrenia. This is expected to complement existing treatments that do not comprehensively cover all symptom domains in schizophrenia.1

https://www.psychiatrictimes.com/view/drug-candidate-for-schizophrenia-alzheimer-disease-approved-to-initiate-phase-2-trial-in-q2-2024